Designing Lipid Nanoparticle Systems for COVID-19 Vaccines
Lipid nanoparticle (LNP) technology is increasingly enabling the clinical potential of genetic drugs. By packaging the nucleic acid polymer in well-defined nanoparticles, LNPs protect the nucleic acid payload in vivo and facilitate intracellular delivery following uptake into target cells by endocytosis.
A notable example is the development of LNP mRNA vaccines, including the Pfizer/BioNTech COVID-19 vaccine B162b2, which is playing a leading role in the global response to the COVID-19 pandemic.
In this webinar, Pieter Cullis, Ph.D. FRSC, FNAI, a professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia, and scientific director & CEO of NanoMedicines Innovation Network, will explore the design of LNP systems and discuss the design of the LNP used in the Pfizer/ BioNTech COVID-19 vaccine
Attend this webinar to discover:
- An overview of how LNP systems work
- How LNP delivery systems are designed
- The efforts that led to the Pfizer/ BioNTech BNT162b2 COVID-19 vaccine